The first patient has been dosed in the P-III trial (FOCUS) evaluating the efficacy and safety of solriamfetol (150 or 300mg) vs PBO in a ratio (1:1:1) in ~ 450 patients with ADHD for 6wks.
The 1EPs of the study will be changed in the adult ADHD investigator symptom report scale (AISRS)
Solriamfetol, a dopamine and norepinephrine reuptake inhibitor. Additionally, Solriamfetol has agonist action at the 5HT1a and trace amine-associated receptor 1 (TAAR1) receptors, according to in vitro studies
Ref: GlobeNewswire | Image: Axsome Therapeutics
Related Post:- Axsome Therapeutics Entered into an Exclusive License Agreement with Pharmanovia to Develop and Commercialize Sunosi (solriamfetol) in Europe
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
